Renin–angiotensin–aldosterone system (RAAS) blockers, which are used widely in most patients with pre-existing hypertension and diabetes, have also been postulated to increase the risk of developing more severe and fatal COVID-19 disease [30]. This evidence concerns the gene REN and hypertensive disorder.